Leap Therapeutics Inc (NASDAQ:LPTX)’s share price shot up 5% during mid-day trading on Friday . The stock traded as high as $1.53 and last traded at $1.46, 130,383 shares were traded during mid-day trading. A decline of 77% from the average session volume of 564,884 shares. The stock had previously closed at $1.39.
Several research firms have issued reports on LPTX. ValuEngine raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Friday.
The company has a market capitalization of $34.13 million, a PE ratio of -0.58 and a beta of 2.35. The company has a current ratio of 1.99, a quick ratio of 2.77 and a debt-to-equity ratio of 0.07. The firm’s 50-day simple moving average is $1.90 and its 200-day simple moving average is $1.73.
A number of institutional investors have recently added to or reduced their stakes in LPTX. FMR LLC boosted its holdings in shares of Leap Therapeutics by 3.9% during the fourth quarter. FMR LLC now owns 957,124 shares of the company’s stock worth $1,914,000 after purchasing an additional 36,300 shares during the period. Deutsche Bank AG boosted its holdings in shares of Leap Therapeutics by 45.7% during the fourth quarter. Deutsche Bank AG now owns 124,338 shares of the company’s stock worth $248,000 after purchasing an additional 39,000 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Leap Therapeutics during the second quarter worth about $42,000. BlackRock Inc. boosted its holdings in shares of Leap Therapeutics by 40.0% during the second quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock worth $61,000 after purchasing an additional 9,782 shares during the period. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Leap Therapeutics during the second quarter worth about $28,000. 8.76% of the stock is owned by institutional investors.
About Leap Therapeutics (NASDAQ:LPTX)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Story: Convertible Shares
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.